The total study population comprised of 375 patients with HER2‐negative, stage II/III breast cancer, amenable to neoadjuvant chemotherapy (129 patients as part of the DIRECT trial and 246 patients as part of the NEOZOTAC trial; Figure 2). Here, ERBB2 is linked to breast carcinoma.